Physician profile
Steven A Kobetz
NPI 1326001280
$26,316.76
in general payments reported to CMS, 2019-2025
75 companies · $4,273 in 2025
The $4,273 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,846 · 2020: $2,398 · 2021: $3,041 · 2022: $3,732 · 2023: $4,402 · 2024: $4,625 · 2025: $4,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,299.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,212.98 | 2021-2025 | |
| Ucb, INC. | $1,883.00 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $1,309.35 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $1,238.82 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $1,044.39 | 2019-2025 | Ultomiris |
| Pfizer INC. | $1,032.12 | 2019-2025 | |
| Lilly USA, LLC | $966.35 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Novartis Pharmaceuticals Corporation | $889.86 | 2019-2025 | |
| Biogen, INC. | $783.07 | 2019-2025 | Vumerity, Skyclarys |
| Acadia Pharmaceuticals INC | $780.56 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $774.12 | 2019-2025 | Ingrezza, Ongentys |
| Eisai INC. | $728.18 | 2019-2025 | |
| Allergan, INC. | $624.83 | 2019-2022 | |
| Argenx US, INC. | $583.93 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $517.47 | 2022-2025 | Vyepti, Rexulti |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kobetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.